[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632475":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":46,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":20,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pola-ZR-Glo","EXPERIMENTAL","Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab",[13],"Drug: Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen","Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 12 cycles.\n\nDosage:\n\nPolatuzumab vedotin (1.8 mg\u002Fkg) will be administered intravenously on Day 2 of Cycle 1 and on Day 1 of Cycles 2-6 (each Q3W).\n\nZanubrutinib (160mg bid p.o.) will be administered from D1 to D21 through Cycles 1-6 Q3W.\n\nLenalidomide (25mg qd p.o.) will be administered from D2 to D11 through Cycles 1-6 Q3W.\n\nGlofitamab will be administered i.v. on a step-up dosing schedule starting on Day 8 of Cycle 1 (2.5 mg), Day 15 of Cycle 1 (10 mg), followed by 30 mg on Day 1 of Cycles 2-12, with each cycle being 21 days. A single dose of obinutuzumab 1000 mg will be administered intravenously on Day 1 of Cycle 1.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Weili Zhao","CONTACT","+862164370045 Ext. 610707","zwl_trial@163.com",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"Pengpeng Xu","pengpeng_xu@126.com",[31],{"facility":5,"status":32,"city":33,"state":20,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Shanghai","200020","China","CN",{"type":38,"coordinates":39},"Point",[40,41],121.45806,31.22222,{"lat":41,"lon":40},[44],{"name":23,"role":24,"phone":45,"phoneExt":20,"email":26},"64370045",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Zhao Weili","Professor and Director, Shanghai Institute of Hematology","100632475","phase-2-the-efficacy-and-safety-of-pola-zr-glo-in-older-treatment-naive-patients-with-lbcl-100632475",false,"NCT07514169","The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL","The Efficacy and Safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) Regimen in Older Treatment-naive Patients With Large B-cell Lymphoma (LBCL)","SILVERGLO","Inclusion Criteria:\n\nPatients must satisfy all of the following criteria to be enrolled in the study:\n\n* Histologically-confirmed large B-cell lymphoma (without central nervous system involvement)\n* Aged ≥ 70 years old with comprehensive geriatric assessment stratified as unfit or frail, or those who decline immunochemotherapy.\n* Eastern Cooperative Oncology Group Performance Status 0-2\n* At least 1 measurable site of disease (defined as lymph nodes with the long diameters longer than 1.5cm, or extra-nodal sites with the long diameters longer than 1.0cm; meanwhile, any lesion site with at least 2 measurable vertical diameters)\n* Life expectancy of at least 3 months determined by researchers\n* The patient or his or her legal representative must provide written informed consent prior to any special examination or procedure for the research.\n* Anti-lymphoma drugs have not been used before (except glucocorticoids)\n\nExclusion Criteria:\n\nPresence of any of the following criteria will exclude a patient from enrollment:\n\n* Uncontrolled blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases\n* Laboratory measures meet the following criteria at screening (unless caused by lymphoma):\n\nNeutrophils\\\u003C1.0×10\\^9\u002FL Platelets\\\u003C75×10\\^9\u002FL ALT or AST is 2.5 times higher than the upper limits of normal (ULN), serum bilirubin are 1.5 times higher than the ULN.\n\neGFR is lower than 30ml\u002Fmin\u002F1.73m\\^2 (according to Cockcroft-Gault Equation or MDRD Equation).\n\n* uncontrollable or significant cardiovascular diseases, including but not limited to: Left ventricular ejection fraction\\\u003C50% Cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy QTc prolongation with clinical significance, QTc interval\\>470ms (females) or 480ms (males), type 2 second-degree atrioventricular block or third-degree atrioventricular block\n* Patients with HbsAg positive are required to have HBV DNA\\\u003C1.0×10\\^3 IU\u002Fml before entering the group. In addition, if the patient is HBsAg negative but HBcAb positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA\\\u003C1.0×10\\^3 IU\u002Fml is required before entering the group\n* Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol\n* HIV-infected patients\n* History of stroke or intracranial hemorrhage within 6 months prior to start of therapy\n* Other medical conditions determined by the researchers that may affect the study","ALL","70 Years",{"count":61,"type":62},30,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen in older treatment-naive patients with large B-cell lymphoma.",[68],"Large B-Cell Lymphoma (LBCL)",[70,71,72,73,74,75,76,77],"large B-cell lymphoma","polatuzumab vedotin","zanubrutinib","lenalidomide","glofitamab","older patients","unfit","frail","2026-05-05",{"date":80,"type":81},"2026-05-08","ACTUAL",{"date":83,"type":81},"2026-03-31",{"date":85,"type":62},"2029-12-31",{"name":5,"class":6},1]